GI Partners acquires Charles River

GI Partners has completed the acquisition of the Contract Development and Manufacturing Organization (CDMO) and Cell Solutions businesses from Charles River Laboratories International, forming a new entity, Rose BioSolutions. The deal signifies a notable reshuffle in the cell and gene therapy supply chain sector, as GI Partners aims to leverage the acquired assets to strengthen its presence in the advanced manufacturing of biopharmaceuticals. Financial details of the transaction remain undisclosed.

The acquisition encompasses the full suite of CDMO and cell solutions services previously offered by Charles River. The newly formed Rose BioSolutions will operate from Wilmington, Massachusetts, where the target's headquarters are located. The asset transfer was finalized on May 7, 2026, according to publicly available transaction summaries. GI Partners, a private investment firm recognized for its strategic acquisitions in life sciences, sees this acquisition as a means to expand its footprint in a rapidly evolving market niche.

GI Partners' decision to integrate these segments into Rose BioSolutions underscores a strategic push to enhance capabilities in cell and gene therapy, segments expected to grow significantly as pharmaceutical companies intensify investments in personalized medicine. The acquired businesses provide advanced manufacturing technologies critical for the development and production of cell and gene therapies, a field marked by high growth potential and complex regulatory demands.

The acquisition comes amid increasing competition in the CDMO sector, driven by rising demand for specialized manufacturing services in the biotech industry. As rival firms also pursue capacity expansions and technological advancements, GI Partners' move places it in direct competition with established players seeking to capitalize on the burgeoning demand for innovative therapies. This competitive landscape underscores the importance of strategic acquisitions to secure technological and operational advantages.

The completion of this transaction adds another layer to GI Partners' investment portfolio, aligning with broader trends in capital allocation favoring life sciences and biopharmaceuticals. Looking ahead, the integration of these assets into Rose BioSolutions will be pivotal as the entity positions itself to address the intricate demands of cell and gene therapy manufacturing, potentially leading to further consolidation in this dynamic sector.